Polly Feigl

TL;DR: Policy issues that influenced the development of policies for inclusion of quality of life end points in certain Southwest Oncology Group clinical trials are reviewed and specific questionnaires with psychometric properties are recommended.

TL;DR: Exploratory analyses suggest that patients with stage III colon cancer with wild-type Ki-ras or no p53 expression benefit from adjuvant 5FU plus levamisole, whereas those with Ki-ra mutations or p53 overexpression do not, and an independent study will be required to determine whether response to adjUvant therapy in colon cancer depends on mutational status.

TL;DR: The PCPT design is described with reference to alternatives that were considered and the chosen design depends on five critical assumptions that must be monitored closely throughout the 9-year trial.

TL;DR: There was a linear trend for older patients to receive fewer services but other age patterns also were found, and age was not significantly associated with clinical staging or estrogen receptors.

TL;DR: Compared with the young, the group aged 65 years or older is at a greater risk for lung cancer and has a higher proportion of lung cancer initially seen at local stage, which indicates selective screening of high-risk target groups may be beneficial.